Leonil Ganlim, MD
Endocrinology, Diabetes & Metabolism · Tupelo, MSNPI 1962512590
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 1,179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 56 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations.
Across 1,179 payments — averaging $16.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- Amgen$1K
- Corcept Therapeutics$1K
- Xeris Pharmaceuticals, Inc.$1K
- Insulet Corporation$1K
- plus $10K from 50 others
What the payments were for
- Food & beverage$18,84999%
- Education$2201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ISTURISA$226
- FREESTYLE LIBRE 3$135
- Watchman$100
How this compares
$19,069 in reported general payments places this provider in the 70th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 24 | $875,020 |
| OzempicSemaglutide | 254 | $269,136 |
| Thiola EcTiopronin | 12 | $187,009 |
| MounjaroTirzepatide | 138 | $144,365 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 95 | $137,714 |
| TrulicityDulaglutide | 73 | $84,724 |
| JardianceEmpagliflozin | 103 | $73,120 |
| Cinacalcet Hcl | 166 | $60,863 |
| Tresiba Flextouch U-100Insulin Degludec | 74 | $57,608 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 39 | $50,387 |
| JanuviaSitagliptin Phosphate | 46 | $35,907 |
| FarxigaDapagliflozin Propanediol | 37 | $29,225 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $25,436 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $23,651 |
| Repatha SureclickEvolocumab | 32 | $23,558 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $1,228 | $875,02024 claims |
| Novo NordiskOzempic, Novolog | $1,700 | $275,881274 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $2,162 | $233,498230 claims |
| Boehringer IngelheimJardiance | $722 | $73,120103 claims |
| MerckJanuvia | $278 | $35,90746 claims |
| AstraZenecaFarxiga | $508 | $29,22537 claims |
| BayerKerendia | $446 | $15,06924 claims |
| AbbVieSynthroid | $618 | $10,778163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Tupelo
- Christy OswaltTupelo$27K
- Mark ShepherdTupelo$17K
- Jayant DeyTupelo$1K
- Eric DyessJackson$885K
- Mark BorcheltGulfport$722K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
- Amanda SchieferJackson$204K
- Delali BlavoSouthaven$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.